Foundation Medicine (FMI) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Foundation Medicine (NASDAQ: FMI):

  • 2/10/2018 – Foundation Medicine was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 2/8/2018 – Foundation Medicine was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Foundation Medicine, Inc. provides molecular information products primarily in the United States. The company offers FoundationOne(TM) a molecular information product for the analysis of routine cancer specimens in a clinical setting. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine, Inc. is based in Cambridge, Massachusetts. “
  • 1/31/2018 – Foundation Medicine was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Foundation Medicine, Inc. provides molecular information products primarily in the United States. The company offers FoundationOne(TM) a molecular information product for the analysis of routine cancer specimens in a clinical setting. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine, Inc. is based in Cambridge, Massachusetts. “
  • 1/29/2018 – Foundation Medicine is now covered by analysts at Goldman Sachs Group Inc. They set a “neutral” rating and a $73.00 price target on the stock.
  • 1/25/2018 – Foundation Medicine was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 1/16/2018 – Foundation Medicine was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/3/2018 – Foundation Medicine was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “sell” rating. According to Zacks, “Foundation Medicine, Inc. provides molecular information products primarily in the United States. The company offers FoundationOne(TM) a molecular information product for the analysis of routine cancer specimens in a clinical setting. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine, Inc. is based in Cambridge, Massachusetts. “
  • 12/27/2017 – Foundation Medicine was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 12/20/2017 – Foundation Medicine was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Shares of Foundation Medicine Inc (NASDAQ FMI) opened at $65.60 on Thursday. The company has a quick ratio of 2.03, a current ratio of 2.24 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $2,278.48, a price-to-earnings ratio of -14.68 and a beta of -0.03. Foundation Medicine Inc has a one year low of $22.40 and a one year high of $75.20.

In other Foundation Medicine news, CEO Troy Cox sold 26,713 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $70.13, for a total value of $1,873,382.69. Following the sale, the chief executive officer now directly owns 224,345 shares in the company, valued at $15,733,314.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Steven J. Kafka sold 23,064 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $70.13, for a total value of $1,617,478.32. Following the completion of the sale, the chief operating officer now owns 61,361 shares in the company, valued at $4,303,246.93. The disclosure for this sale can be found here. Insiders sold 228,717 shares of company stock worth $14,987,592 over the last quarter. 2.70% of the stock is currently owned by company insiders.

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply